Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Indianapolis: Eli Lilly and Company has announced the U.S. Food and Drug Administration (FDA) has approved Zepbound ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

The Senate’s approval came shortly after the shutdown deadline. President Biden was expected to sign the bill, and preparations to close government agencies were called off. Trump Wanted ...